Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology

Benjamin Kelmendi, Thomas G. Adams, Steven Southwick, Chadi G. Abdallah, John H. Krystal

Research output: Contribution to journalReview articlepeer-review

15 Scopus citations

Abstract

Thirty years of research on the biology of posttraumatic stress disorder now provides a foundation for hypotheses related to the mechanisms underlying the pharmacotherapy of this disorder. Only two medications, sertraline and paroxetine, are approved by the U.S. Food and Drug Administration for the treatment of PTSD. Although these medications are somewhat effective, other treatment mechanisms must be explored to address the unmet need for effective treatment. This article provides a concise summary of advances in our understanding of the neurobiology of PTSD and novel approaches to pharmacotherapy.

Original languageEnglish
Pages (from-to)281-297
Number of pages17
JournalClinical Psychology: Science and Practice
Volume24
Issue number3
DOIs
StatePublished - Sep 2017

Bibliographical note

Publisher Copyright:
Published 2017. This article is a U.S. Government work and is in the public domain in the USA.

Keywords

  • gamma-amino-butyric acid
  • glutamate
  • noradrenergic
  • pharmacology
  • posttraumatic stress disorder
  • serotonin

ASJC Scopus subject areas

  • Clinical Psychology

Fingerprint

Dive into the research topics of 'Posttraumatic Stress Disorder: An Integrated Overview of the Neurobiological Rationale for Pharmacology'. Together they form a unique fingerprint.

Cite this